Comparative Pharmacology
Head-to-head clinical analysis: RELA versus ROBAXISAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RELA versus ROBAXISAL.
RELA vs ROBAXISAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RELA (Carisoprodol) is a centrally acting muscle relaxant that modulates GABA-A receptor activity and blocks interneuronal activity in the descending reticular formation and spinal cord, resulting in muscle relaxation without directly affecting the neuromuscular junction. Its metabolite, meprobamate, contributes to anxiolytic and sedative effects.
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism is not fully understood, but it is believed to involve general central nervous system depression and inhibition of polysynaptic reflexes in the spinal cord. Aspirin inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis, which provides analgesic and anti-inflammatory effects, and also irreversibly inhibits platelet aggregation.
Adults: 250-350 mg orally 3-4 times daily.
Oral: 2 tablets (methocarbamol 750 mg / aspirin 650 mg) 4 times daily.
None Documented
None Documented
Terminal elimination half-life approximately 20–30 hours; prolonged in elderly and renal impairment
Methocarbamol: 1.0–2.0 hours (prolonged in renal impairment); guaifenesin: approximately 1 hour.
Primarily renal excretion of unchanged drug and metabolites; 70% to 80% eliminated via urine, remainder biliary/fecal
Methocarbamol: renal (primarily as glucuronide and sulfate conjugates, with <2% unchanged); guaifenesin: renal (metabolites, <1% unchanged). No significant biliary/fecal elimination.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant